XML 41 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and Summary of Significant Accounting Policies (Tables)
12 Months Ended
Jun. 30, 2020
Reconciliation of Deferred Revenue Balances A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:

 

 

Years Ended June 30,

 

 

 

2020

 

 

2019

 

Deferred revenue - beginning balance

 

$

2.2

 

 

$

2.6

 

Revenue recognized

 

 

(7.2

)

 

 

(7.9

)

Prepayments

 

 

37.8

 

 

 

7.5

 

Deferred revenue - ending balance

 

$

32.8

 

 

$

2.2

 

 

Schedule of Company's Revenue by Type

 

The following table represents the Company’s revenue by type for the years ended June 30, 2020, 2019, and 2018:

 

 

Years Ended June 30,

 

(In millions)

 

2020

 

 

2019

 

 

2018

 

Molecular diagnostic revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Hereditary Cancer Testing

 

$

347.4

 

 

$

479.7

 

 

$

471.4

 

GeneSight

 

 

74.1

 

 

 

112.6

 

 

 

124.9

 

Prenatal

 

 

76.7

 

 

 

104.9

 

 

 

 

Vectra

 

 

39.1

 

 

 

48.3

 

 

 

55.2

 

Prolaris

 

 

24.7

 

 

 

25.5

 

 

 

21.5

 

EndoPredict

 

 

10.5

 

 

 

10.4

 

 

 

8.8

 

Other

 

 

14.4

 

 

 

8.0

 

 

 

8.6

 

Total molecular diagnostic revenue

 

 

586.9

 

 

 

789.4

 

 

 

690.4

 

Pharmaceutical and clinical service revenue

 

 

51.7

 

 

 

61.7

 

 

 

53.3

 

Total revenue

 

$

638.6

 

 

$

851.1

 

 

$

743.7

 

 

Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations

The following is a reconciliation of the denominators of the basic and diluted earnings per share computations:

 

 

 

Years Ended June 30,

 

 

 

2020

 

 

2019

 

 

2018

 

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares outstanding used to

   compute basic EPS

 

 

74.3

 

 

 

73.5

 

 

 

69.4

 

Effect of dilutive stock options

 

 

 

 

 

2.5

 

 

 

2.6

 

Weighted-average shares outstanding and dilutive

   securities used to compute diluted EPS

 

 

74.3

 

 

 

76.0

 

 

 

72.0

 

Schedule of Anti-Dilutive Options and Restricted Stock Units Excluded from EPS Computation These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:

 

 

 

Years Ended June 30,

 

 

 

2020

 

 

2019

 

 

2018

 

Anti-dilutive options and RSUs excluded from EPS

   computation

 

 

5.5

 

 

 

0.8

 

 

 

 

Accumulated Foreign Currency Adjustment Attributable to Parent [Member]  
Schedule of Cumulative Translation Adjustments Included in Accumulated Other Comprehensive Loss

The following table shows the cumulative translation adjustments included in accumulated other comprehensive loss:

 

Ending balance June 30, 2019

 

$

(7.2

)

Period translation adjustments

 

 

(0.6

)

Reclassification upon deconsolidation of subsidiary

 

 

1.3

 

Ending balance June 30, 2020

 

$

(6.5

)